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strategy in a contemporary series of patients
undergoing coronary artery bypass grafting ? a
two-center study
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Jean-Louis de Brux2 and Christophe Baufreton2Abstract
Objective: The profile of patients referred for coronary artery bypass grafting (CABG) is continuously changing
to include older patients with multiple comorbidities. We assessed the safety and efficacy of a biocompatible
perfusion strategy (BPS) in a contemporary series of patients undergoing isolated CABG.
Methods: BPS consisted of a membrane oxygenator, tip-to-tip closed-system heparin-bonded cardiopulmonary
bypass circuits without a cardiotomy reservoir, low systemic anticoagulation (target ACT ? 250-300 sec) using
heparin titration curves, low prime volume, avoidance of systemic cooling, and routine use of cell saver and
anti-fibrinolytics. Data were prospectively collected using the American Society of Thoracic Surgeons National
Adult Cardiac Surgery Database definitions.
Results: 964 consecutive patients (mean age 66 ? 11 years, 83% male) undergoing CABG between 2008 and 2012
were enrolled. 30-day mortality was 1.4%. Rates of postoperative stroke, myocardial infarction, sternal infection and
reoperation for bleeding were 0.9%, 1.3%, 1.9% and 4.2%, respectively. Average 24-hour chest tube drainage was
440 ? 280 ml. Blood products were used in 34% of patients (total donor exposure of 1.7 ? 4.7 units/patient). Predictors
of hospital mortality in multivariable analysis were left main disease and preoperative treatment with anti-arrhythmic or
immunosuppressive medications. Predictors of allogeneic blood transfusions included older age, small body surface
area, female gender, increased serum creatinine, lower preoperative LVEF and hematocrit. Priority of surgery, dual
antiplatelet therapy and cardiopulmonary bypass time were not predictors of adverse outcomes or blood transfusions.
Conclusions: In a contemporary cohort of patients undergoing CABG, the use of BPS is safe and effective. It is
associated with excellent clinical outcomes and reduced allogeneic blood transfusions.
Keywords: Cardiopulmonary Bypass, Coronary Artery Bypass Grafting, Biocompatible, Clinical outcomes, Blood
TransfusionsBackground
The use of cardiopulmonary bypass (CPB) in coronary
artery bypass grafting (CABG) surgery affords the op-
portunity to achieve the most important goals of this
operation ? complete revascularization, and performing
the anastomoses in an ideal setting of bloodless and* Correspondence: ozshapira@hadassah.org.il
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unless otherwise stated.motionless field ? hence very precisely. These factors
translate into clinical benefits of improved patient sur-
vival and reduced rates of cardiac events and coronary
re-interventions compared to either percutaneous cor-
onary intervention (PCI) or off-pump CABG [1,2].
However, the use of CPB is associated with side-effects
and complications inherent to the pathophysiology of this
technology which involve a mechanical pump, blood-
foreign surface interaction, blood-air interface and micro-his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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matory response, coagulopathy and organ dysfunction [3].
To attenuate these pathophysiological phenomena we
and others developed a unique and comprehensive bio-
compatible perfusion strategy (BPS) in the mid 1990 ? s
and have shown that indeed this strategy is safe and
associated with improved clinical outcomes in patients
undergoing CABG, valve and aortic operations [4-8].
Since these reports, however, the profile of patients
referred for CABG has fundamentally changed to include
older patients with multiple co-morbidities [9]. Patients
often are referred in the setting of acute coronary syn-
drome on dual anti-platelet therapy and after one or more
PCIs [10].
Given this substantially higher patient risk profile we
aimed to reassess the safety and efficacy of our BPS in a
contemporary cohort of patients undergoing CABG.
The BPS was independently adopted by the University
of Angers in the late 1990 ? s [11] and was introduced to
Hadassah in the beginning of 2008. In this study we




964 consecutive patients undergoing isolated CABG
using CPB between January, 2008 and June, 2012 were
enrolled. Patients undergoing off-pump CABG or CABG
with concomitant procedures were excluded. The study
was approved by the Hadassah Hebrew University Medical
Center and the University of Angers Helsinki Committees.
The need for informed consent was waived by both com-
mittees since this was a retrospective study using unidenti-
fied data obtained from Departmental databases.
Biocompatible perfusion strategy
The components of our biocompatible perfusion strategy
have been previously described [4,5]. Both institutions
used an identical uniform protocol. The BPS was adopted
by the entire faculty in Angers and two surgeons (out of
four) at Hadassah. Briefly, it consisted of tip-to-tip, closed-
system (collapsible closed venous reservoir) heparin-
coated CPB circuits (Carmeda?, Medtronic, Minneapolis,
MN, USA, or Bioline?, Maquet, Wayne, NJ, USA) with a
membrane oxygenator and lack of a cardiotomy reservoir.
This circuit configuration nearly eliminates the blood-
air interface. Anticoagulation was carefully monitored
using heparin titration curves (Hepcon?, HMS Plus,
Medtronic, Minneapolis, MN, USA) with a target acti-
vated clotting time (ACT) of 250 ? 300 sec. CPB prime
volume was reduced to a minimum using the retro-
grade autologous priming technique [12]. An important
safety practice is strict avoidance of blood stasis within
the CPB circuits, i.e. ? the volume of blood within asegment of circuit that has no flow must be replaced by a
crystalloid solution. Systemic body temperature was kept
at near-normothermia (34-36?C) avoiding active cooling.
We routinely used a cell saver and anti-fibrinolytics (Tran-
examic acid). The threshold for red blood cell transfusion
was set at hematocrit of less than 20% during CPB and less
than 25% after CPB. Persistent postoperative bleeding in
excess of 300 mL in the first hour or 500 mL in the first
two hours was considered to be an indication for platelet
(5 ? 10 units) and fresh frozen plasma (2 units), in the
presence of supporting laboratory test results. We did
not use thromboelastography. Routine postoperative phar-
macological management included oral administration of
100 mg acetylsalicylic acid once daily, started on the first
postoperative day, and subcutaneous injection of 1 mg/Kg
of enoxaparin started on the first postoperative day and
terminated at discharge. Patients with indwelling drug-
eluting coronary stents implanted within one year before
surgery were treated with oral 75 mg clopidogrel daily in
addition to acetylsalicylic acid.
Data collection and study endpoints
Data in both institutions were prospectively collected and
entered into a Departmental database. Data collection
was performed using the American Society of Thoracic
Surgeons (STS) Adult Cardiac Surgery Database definitions
using the STS collection tool version 2.73 [13]. Routine
prospective data collection optimized two fundamental
requirements ? data completeness and accuracy. Data
collected included baseline patient demographic and
risk profile, operative data and 30-day clinical outcomes.
The primary study endpoints included 30-day mortality
and the incidence and magnitude of allogeneic blood
transfusions. Secondary endpoints included rates of major
complications including perioperative myocardial infarc-
tion, stroke, re-exploration for bleeding and sternal wound
infection, time on the respirator and length of hospital
and intensive-care unit stay. We focused on these end-
points to assess the safety of the BPS, particularly with
regards to the risk of thromboembolic events secondary
to low systemic anticoagulation. Bleeding and transfusion
requirements were used as endpoints to assess the impact
of the BPS on cardiopulmonary-bypass-associated coagu-
lopathy. The STS Database criteria were used to define
the primary and secondary endpoints [13].
Statistical analysis
Continuous variables were expressed as mean ? standard
deviation, median and range. Categorical data were ex-
pressed as absolute values with percentages. To examine
the primary study- endpoints we performed univariable
and multivariable analyses. Continuous variables were
analyzed using the Student t test. Categorical data were
analyzed using the X2 with Yate? s correction. Variables with
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logistic regression models to determine independent pre-
dictors of primary study endpoints. Results were expressed
as odds ratios (OR) with 95% confidence intervals (CI). A
P value of 0.05 was considered significant. Statistical ana-
lyses were performed using the SPSS for Windows, Version
18.0 software.Results
Patients
There were 964 patients (males ? 804 {83%}, females ?
160 {17%}) with a men age of 66 ? 11 years (range 32 to
89 years). The patients ? baseline profile is depicted in
Table 1. It reflects the typical profile of patients referred
for CABG nowadays. Notably, 36% of patients were
diabetics, 40% had left main disease, 57% had prior MI,
29% had prior PCI and many had been on aspirin, a
second antiplatelet agent or heparin.Table 1 Baseline patient profile
Variable Percent or mean,
SD (Median, Range), (n = 964)
Age (Years) 66 ? 11 (66, 32 ? 89)
Gender (M/F) 804 (83%) / 160 (17%)
Hypertension 694 (72%)
Diabetes mellitus 345 (36%)
Peripheral vascular disease 184 (19%)
Prior cerebrovascular accident 62 (6%)
Renal failure on dialysis 13 (1.3%)
Chronic obstructive pulmonary disease 90 (9%)




Preoperative intra-aortic balloon pump 42 (4.3%)
Preoperative medications
Aspirin 878 (91%)




Anti-arrhythmic medication 32 (3%)
Immunosuppression 19 (2%)
Left ventricular ejection fraction (%) 53 ? 12 (55, 5 ? 86)
Extent of coronary artery disease
Left main disease 386 (40%)
Single vessel 48 (5%)
Two vessel 287 (30%)
Three vessel 628 (65%)Operative and perfusion profile
Operative data are summarized in Table 2. A large pro-
portion of patients were operated non-electively. The
mean number of grafts reflects the fact that most pa-
tients were operated for left main or multi-vessel disease
and our strong desire to achieve complete revasculariza-
tion. The left internal mammary artery was used routinely
to graft the left anterior descending coronary artery,
regardless of age. Multiple arterial grafts were preferred
in patients younger than 70 years of age. Inherent to
our perfusion strategy, total heparin and protamine doses
were very low compared to conventional standards, result-
ing in a low ACT.Clinical outcomes
Clinical outcomes are summarized in Table 3. The ob-
served major study outcomes were compared to the
expected outcomes calculated using the STS Database risk
assessment algorithms [13]. Thirty-day mortality, stroke,
myocardial infarction and reoperation for bleeding were
low and within the STS predicted rates. Overall the rate of
postoperative renal failure was higher than expected (7.4%
vs. 3.0%), although only 2.9% required dialysis. The low
rates of major complications translated into short time on
the respirator, and short ICU and hospital length of stay.
In a subset analysis we compared the results of the two
institutions. Clinical outcomes were similar between the
two institutions (data not shown).Table 2 Operative and perfusion data
Variable Percent or mean,






Redo surgery 14 (1.5%)
Number of vessels bypassed 2.7 ? 0.8 (3, 1 ? 5)
Usage of arterial grafts
Left internal mammary artery 938 (97%)
Right internal mammary artery 267 (28%)
Radial artery 125 (13%)
Cardiopulmonary bypass time (min) 95 ? 31 (93, 19 ? 309)
Aortic cross-clamp time (min) 64 ? 21 (63, 12 ? 169)
Lowest systemic temperature (?C) 35 ? 12 (35, 26 ? 37)
Total heparin dose (mg/Kg) 1.9 ? 1.0 (1.7, 0.1-8.6)
Total protamine dose (mg/Kg) 1.0 ? 0.5 (0.9, 0 ? 5.4)
Highest ACT during CPB (sec) 360 ? 326 (335, 130 ? 999)
Lowest ACT during CPB (sec) 273 ? 42 (264, 139 ? 524)
Table 3 Clinical outcomes
Outcome Observed
rate (n = 964)
STS expected
rate* n = 964)
30-day mortality 14 (1.4%) 2.0%
Reoperation for bleeding 41 (4.2%) 6.0%
Postoperative stroke 9 (0.9%) 1.0%
Postoperative sternal infection 18 (1.9%) 0.5%
Postoperative renal failure 71 (7.4%) 3.0%
Postoperative MI 13 (1.3%)
Postoperative atrial fibrillation 241 (25%)
Time on the respirator (hours) 14 ? 29 (8, 2 ? 432)
ICU length of stay (hours) 74 ? 73 (48, 0 ? 1008)
Hospital length of stay (days) 8 ? 7 (10, 2 ? 142)
*Predicted outcome rate based on the American Society of Thoracic Surgeons
Database risk-assessment algorithms [13].
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The data on bleeding and transfusion are summarized in
Table 4 and Figure 1. Median 24-hour chest tube drainage
was 380 ml. Two thirds of the patients did not receive any
allogeneic blood product during their admission. Those
receiving blood products were exposed to a small number
of donors. Discharge hematocrit was lower than the
admission, but greater than 30% and without apparent
adverse clinical effects.Predictors of study end-points
Using multivariable logistic regression analyses we assessed
the predictors of 30-day mortality and allogeneic blood
transfusions. The data are summarized in Table 5. Inde-
pendent predictors of mortality include left main disease
and preoperative treatment with anti-arrhythmic and im-
munosuppressive medications. Independent predictors
of allogeneic transfusions include advanced age, small
body surface area and female gender. High preoperativeTable 4 Bleeding and transfusion data
Variable Percent or mean,
SD (Median, range) n = 964)
24-hour chest tube drainage (ml) 439 ? 280 (380, 8 ? 2740)
Allogeneic blood products transfusion 325 (33.7%)
Magnitude of Donor Units Transfused
Red Blood Cells (units) 1.0 ? 1.9 (0, 0 ? 17)
Fresh Frozen Plasma (units) 0.3 ? 1.2 (0, 0 ? 18)
Platelets (units)* 0.3 ? 1.8 (0, 0 ? 22)
Cryoprecipitate (units)* 0.1 ? 1.1 (0, 0 ? 20)
Total (units) 1.7 ? 4.7 (0, 0 ? 70)
Preoperative hematocrit (%) 40.7 ? 4.6 (41.1, 24.0-56.9)
Discharge hematocrit (%) 33.4 ? 9.3 (32.9, 22.7-28.4)
*One pack of platelets contains five units (five donors) and one pack of
cryoprecipitate contains ten units (ten donors).hematocrit and LVEF were associated with reduced risk
of transfusions. Advanced age and priority of surgery
were not predictors of mortality. Also, the study site
(Hadassah or Angers) and dual anti-platelet therapy
were not predictors of mortality, or blood transfusions.
Discussion
The mid-term results of the Syntax trial published recently
re-confirmed that CABG is associated with improved
survival and fewer major adverse cardiac events com-
pared to PCI in patients with multi-vessel and complex
left main coronary artery disease [1]. These advantages
are particularly apparent in diabetic patients [14]. The
superiority of CABG is related to a fundamental attribute
of the procedure ? the ability to achieve a long-lasting
complete myocardial revascularization. Precise vascular
anastomoses are an important determinant of short and
long-term graft patency. Use of CPB provides the optimal
conditions necessary to perform the anastomoses includ-
ing stable hemodynamics and bloodless and motionless
surgical field. Although in selected and very experienced
center the goals of CABG can be achieved using the
beating-heart technique, recent large scale trials studies
have shown that the off-pump CABG technique is at best
similar or inferior to the on-pump technique [2,15]. How-
ever, use of CPB is associated with side effects inherent to
the technology [3].
The side effects inherent to CPB originate mostly
from exposure of blood to a large foreign surface, the
non-physiological blood-air interphase, mandatory anti-
coagulation, physical trauma to blood components, micro-
embolization and hypothermia [3]. These primary processes
induce activation of multiple cascades such as the intrinsic
and extrinsic coagulation system, the complement and
kalikrein systems as well as cellular components, leading to
intense systemic inflammatory response. Altogether, these
pathophysiological processes result in coagulopathy and
end-organ dysfunction [3].
The comprehensive biocompatible perfusion strategy
adopted by both institutions addresses many of these
issues. We use membrane oxygenators and CPB circuits
with modified surface coated with heparin and avoid sys-
temic cooling, exposing the blood to a more physiologic
conditions and allowing us to employ much lower level
of systemic anticoagulation. Precise monitoring of anticoa-
gulation by heparin titration curves in addition to ACT,
reduces over- or under dosing of heparin and protamine.
Using a closed CPB system without a cardiotomy sucker
and a reservoir minimizes the deleterious effects of blood-
air interphase. Reducing CPB prime decreases hemodilu-
tion. Altogether this set of modifications comprising the
BPS result in a marked attenuation of the inflammatory
response and coagulopathy [16-18], translating into im-
proved clinical outcomes and reduced need for allogeneic
Figure 1 The incidence and magnitude of allogeneic blood product transfusions. RBC: Red blood cells; FFP: Fresh frozen plasma; PLT: Platelets.
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strategy [4-8,11].
The baseline profile of the current patient cohort is
typical for patients referred for CABG nowadays [9].
Patients are older with multiple co-morbidities (36%
were diabetics). Most patients had left main and or 3-
vessel disease. Fifty eight percent had prior MI and 29%
underwent at least one PCI prior to surgery. CABG was










12.98 2.38 ? 70.8 0.003
Preoperative anti-arrhythmics 6.86 1.74 ? 27.11 0.006
Left main disease 5.77 1.48 ? 22.5 0.012
B. Allogeneic blood product transfusions
Age 1.05 1.03 ? 1.06 <0.0001
Body surface area 1.004 1.00 ? 1.007 0.025
Female gender 5.07 3.26 ? 7.89 <0.000
Preoperative creatinine 1.65 1.15 ? 2.36 0.007
LVEF 0.97 0.95 ? 0.98 <0.0001
Preoperative hematocrit 0.85 0.81 ? 0.88 <0.0001profile, this study demonstrates that the comprehensive
BPS remains safe and effective.
The single most important outcome measure to assess
quality and safety is procedural mortality. We observed
a 30-day mortality of 1.4%. This is much less than the
2.0% expected by the STS Database algorithm. The STS
Database risk prediction models are derived from data
collected on more than two million CABG procedures.
Thus, although the current study lacks a control group,
the STS risk prediction models for mortality and specific
complications serve as very powerful benchmarks against
which our results can be compared [19].
Safety is a major concern with any technique and tech-
nology that deviates from standard practice. Despite using
significantly lower level of systemic anticoagulation, we
did not observe clots in the CPB circuits or experienced
oxygenator malfunction. More importantly, the rates of
postoperative thromboembolic complications such as
CVA, MI and peripheral vascular were low and within
expected, based on the STS predictive algorithms.
The BPS was not only safe, but also effective. Despite
the high risk profile, clinical outcomes were very accept-
able. The observed operative mortality of 1.4% was lower
than the STS predicted mortality of 2.0%. Independent
predictors of 30-day mortality were left main and pre-
operative use of immunosuppressive or anti-arrhythmic
medications. Factors such as age, female gender, diabetes,
renal failure, non-elective procedure and cardiopulmonary
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mortality.
The low rate of CVA (0.9%) observed in the current
series despite the increased patient risk profile is encour-
aging. CVA has been considered as the "Achilles heel" of
CABG compared with PCI even in recent studies such
as Syntax [1]. We attribute the low CVA rate to several
factors associated with the BPS. The elimination of the
cardiotomy suction from the CPB circuit minimizes blood-
air interface, substantially decreasing micro-embolization
and systemic inflammatory response ? well known risk
factors for neurological adverse events. Using transcra-
nial Doppler technology, we have previously shown that
the number of cerebral micro-emboli was very low and
associated with low rates of CVA and neurocognitive
dysfunction [5]. In that same study we have also shown
that the low anticoagulation protocol reduces thrombin
generation during CPB, potentially reducing the risk of
thromboembolic complications [5]. In fact, the incidence
of other thromboembolic complications we observed such
as MI (1.3%) was lower than expected by the STS predic-
tion for our cohort. We did observe a relatively higher rate
of postoperative renal failure. Although it is within the
range reported recently after CABG [20], our rate is higher
than the STS-predicted. We have no good explanation for
this observation and plan to further investigate it.
The BPS was particularly effective in reducing bleeding
and transfusion requirements. The observed rate of 4.2%
for reoperation bleeding was lower than that predicted
by the STS algorithm (6%) for our cohort. Median 24-
hour chest tube drainage was 380 ml. Coagulopathy was
very infrequently the cause for reoperation. Two thirds
of patients did not receive any allogeneic blood products
with an average total donor exposure of only 1.7 units.
This compares favorably with reported transfusion rates
of 39-70% in recent large-scale reports [21-24]. In contrast
to these reports, advanced age, priority of surgery, pre-
operative dual anti-platelet therapy and CPB times were
not found to be risk factors of increased transfusion. The
protective effect of the BPS in patients on dual-antiplatelet
therapy has been also reported by Hussaini and colleagues.
[25]. It has been previously demonstrated that reoperation
for bleeding, the incidence transfusion and the magnitude
allogeneic blood transfusion are all independent risk
factors of adverse outcomes after cardiac surgery [21-24].
We believe that the favorable clinical outcomes observed
in the current study are strongly related to reduced bleed-
ing and very low rate of allogeneic blood product
utilization. Finally, reduced rates of major complications,
bleeding and transfusion requirements translated into
short respiratory support times, short ICU and total hos-
pital lengths of stay.
There are prior studies that found limited value and
small clinical benefit to biocompatible CPB circuits [26].A careful look at these studies reveals that the perfusion
technique practiced by different authors was highly vari-
able, missing many essential components of our compre-
hensive BPS. Examples include using open (versus closed)
systems, using CPB circuits that are not tip-to-tip coated,
inclusion of cardiotomy suction and conventional levels of
systemic anticoagulation. We strongly believe that in order
to be truly biocompatible and clinically effective, our BPS
should be implemented as a whole. Eliminating one or
more components might have a major adverse impact on
its biocompatibility.
This study was not designed to evaluate the cost-
effectiveness of the BPS. However, it seems that the
apparent clinical benefits may very well counter-balance
the incremental cost of the technology. LaPar and col-
leagues recently demonstrated the substantial cost saving
achieved by reducing blood transfusions after isolate
CABG [24]. This aspect mandates further investigation
in our institutions.
Study limitations. Although the data were entered pro-
spectively, this is a retrospective study with the inherent
limitation of a selection bias. However, the study cohort
is large, consecutive and typical of contemporary practice,
allowing meaningful multivariable analyses of outcomes.
Although both centers employed a similar perfusion
strategy, non-measured differences in practice between
institutions might have affected outcomes. Finally, there
is no control group. However, the use of the STS risk
prediction models provides benchmarks against which
the outcomes of this series can be compared. In fact,
given our previous prospective randomized trials and
the results of the current study, it would be difficult to
ethically justify such a trial.
Conclusions
Despite the study limitations, we conclude that the our
data suggest that in a contemporary cohort of patients
undergoing CABG, the use of BPS is safe and effective. It
is associated with excellent clinical outcomes and reduced
allogeneic blood transfusions.
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